(919) 224-8800 Contact Our Team

During this presentation, you'll learn about:
  • History of FDA approval of immune checkpoint inhibitors
  • Combination therapies, including chemotherapy and radiotherapy; cytokines; vaccines; and other “new stars”
  • Other targeted therapies
  • Use of prognostic and monitoring biomarkers

Presented by:
Peter Langecker, MD, PhD
Executive Medical Director, Global Oncology, Clinipace Worldwide
Peter has over 25 years of extensive hands-on experience in establishing and conducting industry-sponsored oncology and hematology clinical research and development according to GCP, GLP and GMP regulations. His primary responsibilities at Clinipace Worldwide include the provision of internal and external drug development, regulatory strategy and medical affairs consulting to Clinipace project teams and clients. Peter’s medical training and published research is focused on preclinical and clinical oncology and the hormonal regulation of breast cancer. He is an author and co-author of over 50 publications and posters.

Free Webcast:

Immune Checkpoint Inhibitors: 
The New Breakout Stars in Cancer Treatment

Download the webcast now

  •